Advertisement
Advertisement
CRSP
CRISPR Therapeutics AG
55.76
USDSponsored
-3.27
-5.54%
Sep 23, 16:00 UTC -4
Closed
After-Market
56.17
+0.41
+0.74%
CRSP Earnings Reports
Positive Surprise Ratio
CRSP beat 21 of 40 last estimates.
53%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$9.71M
/-$1.05
Implied change from Q2 26 (Revenue/ EPS)
-4.59%
/+11.70%
Implied change from Q3 25 (Revenue/ EPS)
+992.70%
/-10.26%
CRISPR Therapeutics AG earnings per share and revenue
On Aug 03, 2026, CRSP reported earnings of -0.94 USD per share (EPS) for Q2 26, beating the estimate of -1.22 USD, resulting in a 23.04% surprise. Revenue reached 10.18 million, compared to an expected 6.93 million, with a 47.02% difference. The market reacted with a +7.06% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 14 analysts forecast an EPS of -1.05 USD, with revenue projected to reach 9.71 million USD, implying an increase of 11.70% EPS, and decrease of -4.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were CRISPR Therapeutics AG's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, CRISPR Therapeutics AG reported EPS of -$0.94, beating estimates by 23.04%, and revenue of $10.18M, 47.02% above expectations.
How did the market react to CRISPR Therapeutics AG's Q2 2026 earnings?
The stock price moved up 7.06%, changed from $49.57 before the earnings release to $53.07 the day after.
When is CRISPR Therapeutics AG expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for CRISPR Therapeutics AG's next earnings report?
Based on 14
analysts, CRISPR Therapeutics AG is expected to report EPS of -$1.05 and revenue of $9.71M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.